- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28 result(s) found for: Filgotinib.
Displaying page 1 of 2.
EudraCT Number: 2016-002763-34 | Sponsor Protocol Number: GS-US-419-3896 | Start Date*: 2017-02-08 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease | |||||||||||||
Medical condition: Moderately to Severely Active Crohn's Disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) AT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IS (Completed) SE (Completed) GR (Completed) PT (Completed) SK (Completed) DE (Completed) ES (Prematurely Ended) BE (Completed) NL (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002765-58 | Sponsor Protocol Number: GS-US-418-3899 | Start Date*: 2017-01-30 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | |||||||||||||
Medical condition: Ulcerative Colitis (UC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) SE (Completed) AT (Completed) PT (Completed) SK (Completed) GR (Completed) FR (Completed) IS (Completed) ES (Ongoing) BG (Prematurely Ended) DE (Completed) NL (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001367-36 | Sponsor Protocol Number: GS-US-419-3895 | Start Date*: 2017-02-08 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to ... | |||||||||||||
Medical condition: Moderately to Severely Active Crohn’s Disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) AT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IS (Completed) SE (Completed) DE (Completed) GR (Completed) PT (Completed) SK (Completed) ES (Completed) BE (Completed) NL (Completed) HR (Completed) NO (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000719-30 | Sponsor Protocol Number: GLPG0634-CL-341 | Start Date*: 2022-08-30 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A randomized, double-blind, controlled, multi-center study to evaluate the efficacy and safety of dose de-escalation of orally administered filgotinib in subjects with ulcerative colitis in clinica... | |||||||||||||
Medical condition: ulcerative colitis (UC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) CZ (Prematurely Ended) FR (Completed) ES (Prematurely Ended) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003179-23 | Sponsor Protocol Number: GS-US-419-4015 | Start Date*: 2017-04-13 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD) | |||||||||||||
Medical condition: Small Bowel Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed) HU (Completed) FR (Completed) AT (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003153-15 | Sponsor Protocol Number: GS-US-419-4016 | Start Date*: 2017-08-01 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease | |||||||||||||
Medical condition: Perianal Fistulizing Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) DE (Completed) PL (Completed) ES (Completed) AT (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000545-52 | Sponsor Protocol Number: GLPG0634-CL-225 | Start Date*: 2017-10-06 | |||||||||||
Sponsor Name:Galapagos Nv | |||||||||||||
Full Title: A multicenter, open-label, long-term extension safety and efficacy study of filgotinib treatment in subjects with moderately to severely active psoriatic arthritis | |||||||||||||
Medical condition: Psoriatic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001392-78 | Sponsor Protocol Number: GS-US-418-3898 | Start Date*: 2017-01-30 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately ... | |||||||||||||
Medical condition: Moderately to Severely Active Ulcerative Colitis (UC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) BE (Completed) SE (Completed) AT (Completed) PT (Completed) GR (Completed) SK (Completed) IS (Completed) ES (Completed) BG (Completed) DE (Completed) NL (Completed) HR (Completed) NO (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003630-25 | Sponsor Protocol Number: GS-US-417-0304 | Start Date*: 2017-06-15 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Trial now transitioned) BE (Completed) CZ (Completed) DE (Trial now transitioned) PL (Completed) ES (Completed) BG (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000568-41 | Sponsor Protocol Number: GS-US-417-0301 | Start Date*: 2016-10-11 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to ... | |||||||||||||
Medical condition: Moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) GB (Completed) BE (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BG (Completed) PL (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002021-29 | Sponsor Protocol Number: GS-US-431-4567 | Start Date*: 2020-09-01 | |||||||||||
Sponsor Name:Gilead Sciences Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are In... | |||||||||||||
Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Completed) HU (Completed) PL (Completed) ES (Temporarily Halted) CZ (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001485-17 | Sponsor Protocol Number: GS-US-432-4097 | Start Date*: 2017-08-15 | |||||||||||||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||||||||||||
Full Title: A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Non-Infectious Uveitis | |||||||||||||||||||||||
Medical condition: Non-infectious Uveitis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001996-35 | Sponsor Protocol Number: GS-US-431-4566 | Start Date*: 2020-03-04 | |||||||||||
Sponsor Name:Gilead Sciences Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naïve to Biologic ... | |||||||||||||
Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) PL (Completed) BG (Completed) ES (Completed) CZ (Completed) NL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000569-21 | Sponsor Protocol Number: GS-US-417-0302 | Start Date*: 2017-01-30 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disea... | |||||||||||||
Medical condition: Moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) DE (Completed) FR (Completed) HU (Completed) ES (Completed) PL (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000570-37 | Sponsor Protocol Number: GS-US-417-0303 | Start Date*: 2016-11-29 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotr... | |||||||||||||
Medical condition: Moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) BE (Completed) GB (Completed) HU (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000402-38 | Sponsor Protocol Number: GS-US-418-4279 | Start Date*: 2018-01-19 | ||||||||||||||||
Sponsor Name:Gilead Sciences, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease | ||||||||||||||||||
Medical condition: To evaluate the testicular safety of filgotinib in adult males with moderately to severely Active Inflammatory Bowel Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed) PT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003637-14 | Sponsor Protocol Number: GLPG0634-CL-224 | Start Date*: 2017-01-26 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... | |||||||||||||
Medical condition: psoriatic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) ES (Completed) CZ (Completed) BE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003636-21 | Sponsor Protocol Number: GLPG0634-CL-223 | Start Date*: 2017-01-26 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 12 weeks to subjects with active ankylosing spondylitis | |||||||||||||
Medical condition: ankylosing spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) CZ (Completed) ES (Completed) BG (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003933-14 | Sponsor Protocol Number: GLPG0634-CL-227 | Start Date*: 2019-05-27 | ||||||||||||||||||||||||||
Sponsor Name:Galapagos NV | ||||||||||||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosin... | ||||||||||||||||||||||||||||
Medical condition: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||||||||||||
Trial protocol: LV (Completed) EE (Completed) BG (Completed) BE (Completed) CZ (Completed) ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003558-34 | Sponsor Protocol Number: GS-US-445-4189 | Start Date*: 2017-07-03 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren’s Syndrome | |||||||||||||
Medical condition: Active Sjogren’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
